This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

'Fast Money' Recap: A Mixed Bag for Housing

NEW YORK (TheStreet) -- The S&P 500 sold off near the end of Tuesday's trading session, closing lower by 0.64%.

On CNBC's "Fast Money" TV show, Guy Adami, managing director of stockmonster.com, said Tuesday's housing data were good but the bond market still refused to selloff. He reasoned that Treasury yields are likely headed lower while the S&P 500 could skid into the end of month, possibly falling to 1,860. 

Brian Kelly, founder of Brian Kelly Capital, said he was surprised the stock market sold off following such positive results from Tuesday's new-home sales. He took profits in his long S&P 500 position. 

Dan Nathan, co-founder and editor of riskreversal.com, said the S&P 500 is unlikely to decline to 1,860. He added that bonds have done well because it's one of the few safe haven assets left for investors to buy. 

Karen Finerman, president of Metropolitan Capital Advisors, said she is more inclined to buy volatility at current levels, than to sell it, despite the CBOE Volatility Index (VIX.X) rallying more than 10%.

Nathan and Finerman said there needs to be more positive data on the housing market to truly confirm that it is improving. Nathan called the housing market a "mixed bag" at the moment.

Adami said Home Depot (HD) seems to be setting up as a solid short-sell candidate. 

Robyn Karnauska, biotechnology analyst at Deutsche Bank, was a guest on the show. She is not a seller of Vertex Pharmaceuticals (VRTX) and still has a buy rating on the stock despite its jump by 40% on Tuesday. The stock popped on positive Phase 3 trial results for its cystic fibrosis treatment. The stock has more upside as the company can afford to raise prices. She added that Pharmacyclics (PCYC) could double in the next 12 months. 

Kelly said the iShares Nasdaq Biotechnology ETF (IBB) is a good way for investors who don't have a lot of knowledge in the biotech space to gain broad exposure to the industry. 

Finerman agreed, adding the exchange-traded fund will provide investors with less volatility than they would have by simply owning individual biotech stocks. 

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs